Skip to main content
. 2023 Nov 30;13(11):e064256. doi: 10.1136/bmjopen-2022-064256

Table 2.

Mortality effect size estimates derived from RCCT array

Intervention ES 95% CI n Source (references, page numbers, listed in data supplement)
UGIT interventions
Any versus UC 1.1 0.9 to 1.34 19 (s210 p402)
1.1 0.87 to 1.4 28 Online supplemental figure S8
H2RA versus PPI 0.96 0.78 to 1.19 12 (s210 p441)
0.91 0.66 to 1.27 12 Online supplemental figure S9
H2RA versus antacids 1.01 0.66 to 1.55 11 (s210 p452)
0.98 0.62 to 1.53 12 Online supplemental figure S10
H2RA versus sucralfate 1.1 0.95 to 1.24 21 (s210 p459)
1.12 0.95 to 1.33 22 Online supplemental figure S11
Antacids versus sucralfate 1.15 0.93 to 1.4 11 (s210 p479)
1.13 0.87 to 1.45 14 Online supplemental figure S12
Other versus other NR
0.97 0.7 to 1.14 16 Online supplemental figure S13
Aggregate 1.05 0.95 to 1.16 103
Feeding interventions
EN versus PN 1.19 0.8 to 1.77 6 (s211 p91)
1.01 0.87 to 1.18 16 Online supplemental figure S14
EN versus EN+PN 0.99 0.84 to 1.16 5 (s211 p98)
1.8 0.92 to 3.5 4 Online supplemental figure S15
EN versus delayed EN 1.0 0.16 to 6.4 1 (s212 p48)
0.74 0.40 to 1.38 7 Online supplemental figure S16
PP versus gastric 1.03 0.83 to 1.29 11 (s213 p50)
1.06 0.77 to 1.46 11 Online supplemental figure S17
Aggregate 1.05 0.92 to 1.19 35
Airway interventions
CTSS versus OTSS 1.02 0.84 to 1.23 5 (s214 p27)
1.04 0.78 to 1.38 5 Online supplemental figure S18
HH versus HME 1.03 0.89 to 1.2 12 (s215 p63)
1.05 0.86 to 1.30 12 Online supplemental figure S19
semirecumbent versus supine NR (s216)
0.95 0.75 to 1.21 9 Online supplemental figure S20
Silver ETT 1.09 0.93 to 1.29 1 (s217 p22)
1.13 0.9 to 1.42 1 Online supplemental figure S20
Aggregate 1.03 0.91 to 1.17 26
Probiotic interventions
0.84 0.58 to 1.22 5 (s218 p30)
0.81 0.62 to 1.06 9 Online supplemental figure S21
Intervention ES 95% CI n source(ref & page number)
Oral care interventions
Chlorhexidine versus UC 1.09 0.96 to 1.23 14 (s219 & s220)
1.13 0.93 to 1.38 12 Online supplemental figure S22 & S25
Toothbrushing 0.84 0.67 to 1.05 5 (s219 & s220)
0.78 0.58 to 1.06 5 Online supplemental figure S23 & S25
Other versus other
0.79 0.50 to 1.24 10 Online supplemental figure S24 & S25
Aggregate 0.97 0.83 to 1.14 33
Antibiotic interventions
TAP+PPAP versus UC 0.75 0.65 to 0.87 17 (s221 p53)
0.84 0.73 to 0.96 18 (s222 p94)
0.77 0.66 to 0.91 19 Online supplemental figure S25S26 & S29
TAP versus UC 0.97 0.79 to 1.2 13 (s221 p53)
0.97 0.87 to 1.07 15 (s222 p97)
0.99 0.78 to 1.26 15 Online supplemental figure S26S27 & S29
TAP+PPAP versus PPAP(=duplex)* 0.98 0.73 to 1.32 7 (s221 p53)
0.92 0.72 to 1.18 7 (s222 p98)
0.91 0.66 to 1.26 7 Online supplemental figure S27S28 & S29
Aggregate 0.86; 0.78 to 0.96 42

Source is either Cochrane review or online supplemental figures in this supplement.

The effect size estimates derived here are all ORs although in the source documents (210–222) these estimates are variously ORs or RRs. Those in bold achieved statistical significance.

The number of studies here differs from the equivalent in the Cochrane reviews as only those studies with mortality data in addition to pneumonia data have been included. The number of studies included in the generation of mortality effect sizes includes those reporting either or both of ICU and late mortality data towards generation of a single mortality effect size.

Duplex studies of antibiotic interventions were those in which the control group received PPAP.

Effect sizes significantly difference from null in bold.

Abbreviations; ICU is Intensive Care Unit, UC is Usual Care, H2RA is Histamine 2 receptor antagonists, PPI is Proton Pump Inhibitors, EN is Enteral nutrition, PN is Parenteral Nutrition, CTSS is Closed Tracheal Secretion Suction, OTSS is Open Tracheal Secretion Suction, HH is Heated Humidification, HME is Heat & Moisture Exchange, ETT is Endotracheal Tube.

*Duplex study is one where the study protocol provides PPAP to control group patients while providing both PPAP and TAP to intervention group patients.

CTSS, Closed Tracheal Secretion Suction; EN, Enteral nutrition; ES, effect size; ETT, Endotracheal Tube; HH, Heated Humidification; HME, Heat & Moisture Exchange; H2RA, Histamine 2 receptor antagonists; ICU, Intensive Care Unit; n, number of studies; NR, not reported; OTSS, Open Tracheal Secretion Suction; PN, Parenteral Nutrition; PPAP, protocolised parenteral antibiotic prophylaxis; PPI, Proton Pump Inhibitors; RR, risk ratio; TAP, topical antibiotic prophylaxis; UC, Usual Care; UGIT, upper gastrointestinal tract.